As of Nov 25
| +0.90 / +2.82%|
The 16 analysts offering 12-month price forecasts for Pfizer have a median target of 39.50, with a high estimate of 52.00 and a low estimate of 34.00. The median estimate represents a +20.17% increase from the last price of 32.87.
The current consensus among 19 polled investment analysts is to Buy stock in Pfizer. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.